Skip to main content

Table 2 Cox proportional hazard regression analysis of preoperative CA19-9 on colorectal cancer outcomes

From: Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study

Outcome Total Normal CEA group Elevated CEA group
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
RFS
 Model1 2.02 (1.79–2.28)  < 0.001 2.34 (1.89–2.90)  < 0.001 1.56 (1.34–1.82)  < 0.001
 Model2 2.02 (1.79–2.28)  < 0.001 2.41 (1.94–2.99)  < 0.001 1.56 (1.34–1.82)  < 0.001
 Model3 1.90 (1.67–2.16)  < 0.001 2.10 (1.66–2.66)  < 0.001 1.54 (1.30–1.81)  < 0.001
 Model4 2.08 (1.75–2.47)  < 0.001 2.01 (1.47–2.74) 0.001 1.68 (1.35–2.08)  < 0.001
OS
 Model1 2.28 (1.96–2.65)  < 0.001 2.85 (2.18–3.72)  < 0.001 1.64 (1.36–1.98)  < 0.001
 Model2 2.26 (1.95–2.63)  < 0.001 3.02 (2.31–3.95)  < 0.001 1.63 (1.35–1.97)  < 0.001
 Model3 2.05 (1.74–2.42)  < 0.001 2.54 (1.89–3.42)  < 0.001 1.55 (1.27–1.90)  < 0.001
 Model4 2.25 (1.80–2.81)  < 0.001 2.20 (1.44–3.35)  < 0.001 1.72 (1.30–2.28)  < 0.001
  1. Note: CA 19–9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, OS overall survival, RFS recurrence-free survival
  2. Model 1 was unadjusted. Model 2 was adjusted for sex (female vs. male), age. Model 3 was adjusted for sex (female vs. male), age, primary site (rectum vs. colon), surgical approach (open resection vs. laparoscopic resection), pathology stage (III → II), lymph node yield (≥ 12 vs. < 12), tumor differentiation (poor-undifferentiated vs. moderate vs. well), mucinous (colloid) type (yes vs. no), lymphovascular invasion / perineural invasion (yes vs. no), adjuvant chemotherapy (yes vs. no). Model 4 was adjusted for sex (female vs. male), age, primary site (rectum vs. colon), surgical approach (open resection vs. laparoscopic resection), pathology stage (III → II), lymph node yield (≥ 12 vs. < 12), tumor differentiation (poor-undifferentiated vs. moderate vs. well), mucinous (colloid) type (yes vs. no), lymphovascular invasion / perineural invasion (yes vs. no), adjuvant chemotherapy (yes vs. no), microsatellite instability (yes vs. no)